SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?


To: mistermj who wrote (2115)8/23/2003 8:20:52 PM
From: dwight martin  Read Replies (2) | Respond to of 2135
 
It has an antiangiogenesis MAB that blocks VEGF2 receptors but not VEGF1 receptors, cell-marker targeting technology using MABs fused with I-131, and some vasopermeability enhancing molecules.

Read the abstract of the top article:

oncology.thelancet.com

Read:

nature.com

jncicancerspectrum.oupjournals.org

biz.yahoo.com

You could check out:

groups.yahoo.com